Rare cancers—Rarity as a cost and value argument

J. Matthias Graf von der Schulenburg; Frédéric Pauer

doi:10.1016/j.jcpo.2016.09.004

Details

Original language	English
Pages (from-to)	54-59
Number of pages	6
Journal	Journal of Cancer Policy
Volume	11
Early online date	9 Sept 2016
Publication status	Published - Mar 2017

Abstract

Here is a paradox in medicine: rare diseases are unusual, but developing a rare disease is quite frequent. This is also true for rare forms of cancer. Almost every 20th person in the world suffers from a rare disease, and about one quarter of all new diagnosed cancers belong to rare cancers. The downside of rare diseases for patients is the difficulty to find the right institution for their treatment, for health care payers it is the costly treatments, and for medical professionals their limited knowledge if they are not specialized in the disease in question. On the other hand, the upside for clinical researchers is that rare diseases are beneficial for their scientific careers, as many clinical and scientific questions are still open. The advantages for the pharmaceutical industry are the premium prices, the special governmental programs to stimulate research, and achieving a dominant position in a small market. To sum up, rare cancers are important for all stakeholders in medical care and deserve more attention from public health research.

Keywords

Cancer, Cost, Health care systems, Rare diseases

ASJC Scopus subject areas

Medicine(all)
Oncology
Medicine(all)
Health Policy

Sustainable Development Goals

SDG 3 - Good Health and Well-being

Cite this

Rare cancers—Rarity as a cost and value argument. / Graf von der Schulenburg, J. Matthias; Pauer, Frédéric.
In: Journal of Cancer Policy, Vol. 11, 03.2017, p. 54-59.

Research output: Contribution to journal › Article › Research

Graf von der Schulenburg, JM & Pauer, F 2017, 'Rare cancers—Rarity as a cost and value argument', Journal of Cancer Policy, vol. 11, pp. 54-59. https://doi.org/10.1016/j.jcpo.2016.09.004

Graf von der Schulenburg, J. M., & Pauer, F. (2017). Rare cancers—Rarity as a cost and value argument. Journal of Cancer Policy, 11, 54-59. https://doi.org/10.1016/j.jcpo.2016.09.004

Graf von der Schulenburg JM, Pauer F. Rare cancers—Rarity as a cost and value argument. Journal of Cancer Policy. 2017 Mar;11:54-59. Epub 2016 Sept 9. doi: 10.1016/j.jcpo.2016.09.004

Graf von der Schulenburg, J. Matthias ; Pauer, Frédéric. / Rare cancers—Rarity as a cost and value argument. In: Journal of Cancer Policy. 2017 ; Vol. 11. pp. 54-59.

Download

@article{0b8ad6952ca849a68c565f9b02df0231,

title = "Rare cancers—Rarity as a cost and value argument",

abstract = "Here is a paradox in medicine: rare diseases are unusual, but developing a rare disease is quite frequent. This is also true for rare forms of cancer. Almost every 20th person in the world suffers from a rare disease, and about one quarter of all new diagnosed cancers belong to rare cancers. The downside of rare diseases for patients is the difficulty to find the right institution for their treatment, for health care payers it is the costly treatments, and for medical professionals their limited knowledge if they are not specialized in the disease in question. On the other hand, the upside for clinical researchers is that rare diseases are beneficial for their scientific careers, as many clinical and scientific questions are still open. The advantages for the pharmaceutical industry are the premium prices, the special governmental programs to stimulate research, and achieving a dominant position in a small market. To sum up, rare cancers are important for all stakeholders in medical care and deserve more attention from public health research.",

keywords = "Cancer, Cost, Health care systems, Rare diseases",

author = "{Graf von der Schulenburg}, {J. Matthias} and Fr{\'e}d{\'e}ric Pauer",

year = "2017",

month = mar,

doi = "10.1016/j.jcpo.2016.09.004",

language = "English",

volume = "11",

pages = "54--59",

}

Download

TY - JOUR

T1 - Rare cancers—Rarity as a cost and value argument

AU - Graf von der Schulenburg, J. Matthias

AU - Pauer, Frédéric

PY - 2017/3

Y1 - 2017/3

N2 - Here is a paradox in medicine: rare diseases are unusual, but developing a rare disease is quite frequent. This is also true for rare forms of cancer. Almost every 20th person in the world suffers from a rare disease, and about one quarter of all new diagnosed cancers belong to rare cancers. The downside of rare diseases for patients is the difficulty to find the right institution for their treatment, for health care payers it is the costly treatments, and for medical professionals their limited knowledge if they are not specialized in the disease in question. On the other hand, the upside for clinical researchers is that rare diseases are beneficial for their scientific careers, as many clinical and scientific questions are still open. The advantages for the pharmaceutical industry are the premium prices, the special governmental programs to stimulate research, and achieving a dominant position in a small market. To sum up, rare cancers are important for all stakeholders in medical care and deserve more attention from public health research.

AB - Here is a paradox in medicine: rare diseases are unusual, but developing a rare disease is quite frequent. This is also true for rare forms of cancer. Almost every 20th person in the world suffers from a rare disease, and about one quarter of all new diagnosed cancers belong to rare cancers. The downside of rare diseases for patients is the difficulty to find the right institution for their treatment, for health care payers it is the costly treatments, and for medical professionals their limited knowledge if they are not specialized in the disease in question. On the other hand, the upside for clinical researchers is that rare diseases are beneficial for their scientific careers, as many clinical and scientific questions are still open. The advantages for the pharmaceutical industry are the premium prices, the special governmental programs to stimulate research, and achieving a dominant position in a small market. To sum up, rare cancers are important for all stakeholders in medical care and deserve more attention from public health research.

KW - Cancer

KW - Cost

KW - Health care systems

KW - Rare diseases

UR - http://www.scopus.com/inward/record.url?scp=85009152849&partnerID=8YFLogxK

U2 - 10.1016/j.jcpo.2016.09.004

DO - 10.1016/j.jcpo.2016.09.004

M3 - Article

AN - SCOPUS:85009152849

VL - 11

SP - 54

EP - 59

JO - Journal of Cancer Policy

JF - Journal of Cancer Policy

ER -

Research@Leibniz University